1
|
Bhalala OG, Beamish J, Eratne D, Summerell P, Porter T, Laws SM, Kang MJ, Huq AJ, Chiu WH, Cadwallader C, Walterfang M, Farrand S, Evans AH, Kelso W, Churilov L, Watson R, Yassi N, Velakoulis D, Loi SM. Blood biomarker profiles in young-onset neurocognitive disorders: A cohort study. Aust N Z J Psychiatry 2025:48674241312805. [PMID: 39825484 DOI: 10.1177/00048674241312805] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/20/2025]
Abstract
INTRODUCTION Young-onset neurocognitive symptoms result from a heterogeneous group of neurological and psychiatric disorders which present a diagnostic challenge. To identify such factors, we analysed the Biomarkers in Younger-Onset Neurocognitive Disorders cohort, a study of individuals <65 years old presenting with neurocognitive symptoms for a diagnosis and who have undergone cognitive and biomarker analyses. METHODS Sixty-five participants (median age at assessment of 56 years, 45% female) were recruited during their index presentation to the Royal Melbourne Hospital Neuropsychiatry Centre, a tertiary specialist service in Melbourne, Australia, and categorized as either early-onset Alzheimer's disease (n = 18), non-Alzheimer's disease neurodegeneration (n = 23) or primary psychiatric disorders (n = 24). Levels of neurofilament light chain, glial fibrillary acidic protein and phosphorylated-tau 181, apolipoprotein E genotype and late-onset Alzheimer's disease polygenic risk scores were determined. Information-theoretic model selection identified discriminatory factors. RESULTS Neurofilament light chain, glial fibrillary acidic protein and phosphorylated-tau 181 levels were elevated in early-onset Alzheimer's disease compared with other diagnostic categories. A multi-omic model selection identified that a combination of cognitive and blood biomarkers, but not the polygenic risk score, discriminated between early-onset Alzheimer's disease and primary psychiatric disorders (area under the curve ⩾ 0.975, 95% confidence interval: 0.825-1.000). Phosphorylated-tau 181 alone significantly discriminated between early-onset Alzheimer's disease and non-Alzheimer's disease neurodegeneration causes (area under the curve = 0.950, 95% confidence interval: 0.877-1.00). DISCUSSION Discriminating between early-onset Alzheimer's disease, non-Alzheimer's disease neurodegeneration and primary psychiatric disorders causes of young-onset neurocognitive symptoms is possible by combining cognitive profiles with blood biomarkers. These results support utilizing blood biomarkers for the work-up of young-onset neurocognitive symptoms and highlight the need for the development of a young-onset Alzheimer's disease-specific polygenic risk score.
Collapse
Affiliation(s)
- Oneil G Bhalala
- Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Parkville, VIC, Australia
- Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia
| | - Jessica Beamish
- Neuropsychiatry Centre, The Royal Melbourne Hospital, Parkville, VIC, Australia
| | - Dhamidhu Eratne
- Neuropsychiatry Centre, The Royal Melbourne Hospital, Parkville, VIC, Australia
- Department of Psychiatry, The University of Melbourne, Parkville, VIC, Australia
| | - Patrick Summerell
- Neuropsychiatry Centre, The Royal Melbourne Hospital, Parkville, VIC, Australia
| | - Tenielle Porter
- Centre for Precision Health, Edith Cowan University, Joondalup, WA, Australia
| | - Simon M Laws
- Centre for Precision Health, Edith Cowan University, Joondalup, WA, Australia
| | - Matthew Jy Kang
- Neuropsychiatry Centre, The Royal Melbourne Hospital, Parkville, VIC, Australia
- Department of Psychiatry, The University of Melbourne, Parkville, VIC, Australia
| | - Aamira J Huq
- Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Parkville, VIC, Australia
| | - Wei-Hsuan Chiu
- Department of Psychiatry, The University of Melbourne, Parkville, VIC, Australia
| | - Claire Cadwallader
- Neuropsychiatry Centre, The Royal Melbourne Hospital, Parkville, VIC, Australia
- Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
| | - Mark Walterfang
- Neuropsychiatry Centre, The Royal Melbourne Hospital, Parkville, VIC, Australia
- Department of Psychiatry, The University of Melbourne, Parkville, VIC, Australia
- The Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia
- School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
| | - Sarah Farrand
- Neuropsychiatry Centre, The Royal Melbourne Hospital, Parkville, VIC, Australia
- Department of Psychiatry, The University of Melbourne, Parkville, VIC, Australia
| | - Andrew H Evans
- Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Parkville, VIC, Australia
| | - Wendy Kelso
- Neuropsychiatry Centre, The Royal Melbourne Hospital, Parkville, VIC, Australia
| | - Leonid Churilov
- Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Parkville, VIC, Australia
| | - Rosie Watson
- Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Parkville, VIC, Australia
- Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia
| | - Nawaf Yassi
- Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Parkville, VIC, Australia
- Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia
| | - Dennis Velakoulis
- Neuropsychiatry Centre, The Royal Melbourne Hospital, Parkville, VIC, Australia
- Department of Psychiatry, The University of Melbourne, Parkville, VIC, Australia
| | - Samantha M Loi
- Neuropsychiatry Centre, The Royal Melbourne Hospital, Parkville, VIC, Australia
- Department of Psychiatry, The University of Melbourne, Parkville, VIC, Australia
| |
Collapse
|
2
|
Zhou W, Ås J, Shore-Lorenti C, Nguyen HH, van de Laarschot DM, Sztal-Mazer S, Grill V, Girgis CM, Stricker BHC, van der Eerden BCJ, Thakker RV, Appelman-Dijkstra NM, Wadelius M, Clifton-Bligh RJ, Hallberg P, Verkerk AJMH, van Rooij JGJ, Ebeling PR, Zillikens MC. Gene-based association analysis of a large patient cohort provides insights into genetics of atypical femur fractures. J Bone Miner Res 2024; 39:1315-1326. [PMID: 39126371 PMCID: PMC11371903 DOI: 10.1093/jbmr/zjae122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/18/2023] [Revised: 06/18/2024] [Accepted: 07/08/2024] [Indexed: 08/12/2024]
Abstract
Several small genetic association studies have been conducted for atypical femur fracture (AFF) without replication of results. We assessed previously implicated and novel genes associated with AFFs in a larger set of unrelated AFF cases using whole exome sequencing (WES). We performed gene-based association analysis on 139 European AFF cases and 196 controls matched for bisphosphonate use. We tested all rare, protein-altering variants using both candidate gene and hypothesis-free approaches. In the latter, genes suggestively associated with AFFs (uncorrected p-values <.01) were investigated in a Swedish whole-genome sequencing replication study and assessed in 46 non-European cases. In the candidate gene analysis, PLOD2 showed a suggestive signal. The hypothesis-free approach revealed 10 tentative associations, with XRN2, SORD, and PLOD2 being the most likely candidates for AFF. XRN2 and PLOD2 showed consistent direction of effect estimates in the replication analysis, albeit not statistically significant. Three SNPs associated with SORD expression according to the GTEx portal were in linkage disequilibrium (R2 ≥ 0.2) with an SNP previously reported in a genome-wide association study of AFF. The prevalence of carriers of variants for both PLOD2 and SORD was higher in Asian versus European cases. While we did not identify genes enriched for damaging variants, we found suggestive evidence of a role for XRN2, PLOD2, and SORD, which requires further investigation. Our findings indicate that genetic factors responsible for AFFs are not widely shared among AFF cases. The study provides a stepping-stone for future larger genetic studies of AFF.
Collapse
Affiliation(s)
- Wei Zhou
- Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands
| | - Joel Ås
- Department of Medical Sciences, Uppsala University Hospital, Uppsala 75185, Sweden
| | - Catherine Shore-Lorenti
- Department of Medicine, School of Clinical Sciences, Monash University, Clayton VIC 3168, Australia
| | - Hanh H Nguyen
- Department of Medicine, School of Clinical Sciences, Monash University, Clayton VIC 3168, Australia
| | - Denise M van de Laarschot
- Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands
| | - Shoshana Sztal-Mazer
- Department of Endocrinology and Diabetes, The Alfred Hospital, Melbourne VIC 3004, Australia
- Department of Public Health and Preventative Medicine, Monash University, Melbourne VIC 3004, Australia
| | - Vivian Grill
- Department of Endocrinology and Diabetes, Western Health, Melbourne VIC 3011, Australia
| | - Christian M Girgis
- Department of Diabetes and Endocrinology, Westmead Hospital, Westmead, NSW 2145, Australia
- Faculty of Medicine and Health, The Sydney University, Camperdown NSW 2050, Australia
| | - Bruno H Ch Stricker
- Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam 3015 GD, The Netherlands
| | - Bram C J van der Eerden
- Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands
| | - Rajesh V Thakker
- Academic Endocrine Unit, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 9DU, United Kingdom
- National Institute for Health Research Oxford Biomedical Research Centre, Oxford OX3 9DU, United Kingdom
| | - Natasha M Appelman-Dijkstra
- Department of Internal Medicine, division endocrinology, Leiden University Medical Center, Leiden 2333 ZA, The Netherlands
| | - Mia Wadelius
- Department of Medical Sciences, Uppsala University Hospital, Uppsala 75185, Sweden
| | | | - Pär Hallberg
- Department of Medical Sciences, Uppsala University Hospital, Uppsala 75185, Sweden
| | - Annemieke J M H Verkerk
- Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands
| | - Jeroen G J van Rooij
- Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands
| | - Peter R Ebeling
- Department of Medicine, School of Clinical Sciences, Monash University, Clayton VIC 3168, Australia
| | - M Carola Zillikens
- Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands
| |
Collapse
|
3
|
Vicente M, Addo-Osafo K, Vossel K. Latest advances in mechanisms of epileptic activity in Alzheimer's disease and dementia with Lewy Bodies. Front Neurol 2024; 15:1277613. [PMID: 38390593 PMCID: PMC10882721 DOI: 10.3389/fneur.2024.1277613] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2023] [Accepted: 01/12/2024] [Indexed: 02/24/2024] Open
Abstract
Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) stand as the prevailing sources of neurodegenerative dementia, impacting over 55 million individuals across the globe. Patients with AD and DLB exhibit a higher prevalence of epileptic activity compared to those with other forms of dementia. Seizures can accompany AD and DLB in early stages, and the associated epileptic activity can contribute to cognitive symptoms and exacerbate cognitive decline. Aberrant neuronal activity in AD and DLB may be caused by several mechanisms that are not yet understood. Hyperexcitability could be a biomarker for early detection of AD or DLB before the onset of dementia. In this review, we compare and contrast mechanisms of network hyperexcitability in AD and DLB. We examine the contributions of genetic risk factors, Ca2+ dysregulation, glutamate, AMPA and NMDA receptors, mTOR, pathological amyloid beta, tau and α-synuclein, altered microglial and astrocytic activity, and impaired inhibitory interneuron function. By gaining a deeper understanding of the molecular mechanisms that cause neuronal hyperexcitability, we might uncover therapeutic approaches to effectively ease symptoms and slow down the advancement of AD and DLB.
Collapse
Affiliation(s)
- Mariane Vicente
- Mary S. Easton Center for Alzheimer's Research and Care, Department of Neurology, David Geffen School of Medicine at University of California, Los Angeles, CA, United States
| | - Kwaku Addo-Osafo
- Mary S. Easton Center for Alzheimer's Research and Care, Department of Neurology, David Geffen School of Medicine at University of California, Los Angeles, CA, United States
| | - Keith Vossel
- Mary S. Easton Center for Alzheimer's Research and Care, Department of Neurology, David Geffen School of Medicine at University of California, Los Angeles, CA, United States
| |
Collapse
|
4
|
D’Angiolini S, Basile MS, Mazzon E, Gugliandolo A. In Silico Analysis Reveals the Modulation of Ion Transmembrane Transporters in the Cerebellum of Alzheimer's Disease Patients. Int J Mol Sci 2023; 24:13924. [PMID: 37762226 PMCID: PMC10530854 DOI: 10.3390/ijms241813924] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2023] [Revised: 09/01/2023] [Accepted: 09/08/2023] [Indexed: 09/29/2023] Open
Abstract
Alzheimer's disease (AD) is the most common neurodegenerative disorder. AD hallmarks are extracellular amyloid β (Aβ) plaques and intracellular neurofibrillary tangles in the brain. It is interesting to notice that Aβ plaques appear in the cerebellum only in late stages of the disease, and then it was hypothesized that it can be resistant to specific neurodegenerative mechanisms. However, the role of cerebellum in AD pathogenesis is not clear yet. In this study, we performed an in silico analysis to evaluate the transcriptional profile of cerebellum in AD patients and non-AD subjects in order to deepen the knowledge on its role in AD. The analysis evidenced that only the molecular function (MF) "active ion transmembrane transporter activity" was overrepresented. Regarding the 21 differentially expressed genes included in this MF, some of them may be involved in the ion dyshomeostasis reported in AD, while others assumed, in the cerebellum, an opposite regulation compared to those reported in other brain regions in AD patients. They might be associated to a protective phenotype, that may explain the initial resistance of cerebellum to neurodegeneration in AD. Of note, this MF was not overrepresented in prefrontal cortex and visual cortex indicating that it is a peculiarity of the cerebellum.
Collapse
Affiliation(s)
| | | | - Emanuela Mazzon
- IRCCS Centro Neurolesi “Bonino-Pulejo”, Via Provinciale Palermo, Contrada Casazza, 98124 Messina, Italy; (S.D.); (M.S.B.); (A.G.)
| | | |
Collapse
|
5
|
Gorelik AJ, Paul SE, Karcher NR, Johnson EC, Nagella I, Blaydon L, Modi H, Hansen IS, Colbert SMC, Baranger DAA, Norton SA, Spears I, Gordon B, Zhang W, Hill PL, Oltmanns TF, Bijsterbosch JD, Agrawal A, Hatoum AS, Bogdan R. A Phenome-Wide Association Study (PheWAS) of Late Onset Alzheimer Disease Genetic Risk in Children of European Ancestry at Middle Childhood: Results from the ABCD Study. Behav Genet 2023; 53:249-264. [PMID: 37071275 PMCID: PMC10309061 DOI: 10.1007/s10519-023-10140-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2022] [Accepted: 03/08/2023] [Indexed: 04/19/2023]
Abstract
Genetic risk for Late Onset Alzheimer Disease (AD) has been associated with lower cognition and smaller hippocampal volume in healthy young adults. However, whether these and other associations are present during childhood remains unclear. Using data from 5556 genomically-confirmed European ancestry youth who completed the baseline session of the ongoing the Adolescent Brain Cognitive DevelopmentSM Study (ABCD Study®), our phenome-wide association study estimating associations between four indices of genetic risk for late-onset AD (i.e., AD polygenic risk scores (PRS), APOE rs429358 genotype, AD PRS with the APOE region removed (ADPRS-APOE), and an interaction between ADPRS-APOE and APOE genotype) and 1687 psychosocial, behavioral, and neural phenotypes revealed no significant associations after correction for multiple testing (all ps > 0.0002; all pfdr > 0.07). These data suggest that AD genetic risk may not phenotypically manifest during middle-childhood or that effects are smaller than this sample is powered to detect.
Collapse
Affiliation(s)
- Aaron J Gorelik
- Department of Psychological and Brain Sciences, Washington University in Saint Louis, One Booking Drive, St. Louis, MO, 63130, USA
| | - Sarah E Paul
- Department of Psychological and Brain Sciences, Washington University in Saint Louis, One Booking Drive, St. Louis, MO, 63130, USA
| | - Nicole R Karcher
- Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA
| | - Emma C Johnson
- Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA
| | - Isha Nagella
- Department of Psychological and Brain Sciences, Washington University in Saint Louis, One Booking Drive, St. Louis, MO, 63130, USA
| | - Lauren Blaydon
- Department of Psychological and Brain Sciences, Washington University in Saint Louis, One Booking Drive, St. Louis, MO, 63130, USA
| | - Hailey Modi
- Department of Psychological and Brain Sciences, Washington University in Saint Louis, One Booking Drive, St. Louis, MO, 63130, USA
| | - Isabella S Hansen
- Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA
| | - Sarah M C Colbert
- Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA
| | - David A A Baranger
- Department of Psychological and Brain Sciences, Washington University in Saint Louis, One Booking Drive, St. Louis, MO, 63130, USA
| | - Sara A Norton
- Department of Psychological and Brain Sciences, Washington University in Saint Louis, One Booking Drive, St. Louis, MO, 63130, USA
| | - Isaiah Spears
- Department of Psychological and Brain Sciences, Washington University in Saint Louis, One Booking Drive, St. Louis, MO, 63130, USA
| | - Brian Gordon
- Department of Radiology, Washington University in Saint Louis, 660 South Euclid Ave, Box 8225, St. Louis, MO, 63110, USA
- Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University, St Louis, MO, USA
| | - Wei Zhang
- Department of Radiology, Washington University in Saint Louis, 660 South Euclid Ave, Box 8225, St. Louis, MO, 63110, USA
| | - Patrick L Hill
- Department of Psychological and Brain Sciences, Washington University in Saint Louis, One Booking Drive, St. Louis, MO, 63130, USA
| | - Thomas F Oltmanns
- Department of Psychological and Brain Sciences, Washington University in Saint Louis, One Booking Drive, St. Louis, MO, 63130, USA
| | - Janine D Bijsterbosch
- Department of Radiology, Washington University in Saint Louis, 660 South Euclid Ave, Box 8225, St. Louis, MO, 63110, USA
| | - Arpana Agrawal
- Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA
| | - Alexander S Hatoum
- Department of Psychological and Brain Sciences, Washington University in Saint Louis, One Booking Drive, St. Louis, MO, 63130, USA
| | - Ryan Bogdan
- Department of Psychological and Brain Sciences, Washington University in Saint Louis, One Booking Drive, St. Louis, MO, 63130, USA.
| |
Collapse
|